MedPath

Meridian Bioscience, Inc.

Meridian Bioscience, Inc. logo
🇺🇸United States
Ownership
Holding, Public
Established
1977-01-01
Employees
515
Market Cap
-
Website
http://www.meridianbioscience.com

Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection

Not Applicable
Completed
Conditions
Suspicion of Being Infected With H.Pylori
Interventions
Device: Modified BreathID
First Posted Date
2012-07-26
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
113
Registration Number
NCT01650831
Locations
🇺🇸

Unimed Center, East Brunswick, New Jersey, United States

Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

Phase 2
Terminated
Conditions
Chronic Liver Disease
Hepatocellular Carcinoma (HCC)
Interventions
Drug: 13C Sodium Octanoate
First Posted Date
2011-09-13
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
20
Registration Number
NCT01433016
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency

Phase 2
Completed
Conditions
Chronic Pancreatitis
Healthy Volunteers
Interventions
Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
First Posted Date
2010-12-14
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
33
Registration Number
NCT01259544
Locations
🇮🇳

Asian Institute of Gastroenterology, Hyderabad, India, Somajiguda, Hyderabad, India

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

Phase 4
Completed
Conditions
Helicobacter Pylori Infection
Interventions
Drug: Omeprezole (Losec)
Drug: Pantoprazole(Controloc)
First Posted Date
2009-01-21
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
123
Registration Number
NCT00825630
Locations
🇮🇱

Rabin Medical Center, Petah Tikva, Israel

BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

Phase 3
Completed
Conditions
Chronic Liver Disease
Interventions
Device: c13 methacetin solution with breath analyzer
First Posted Date
2008-08-18
Last Posted Date
2023-01-12
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
414
Registration Number
NCT00736840
Locations
🇮🇱

Carmel Medical Center, Haifa, Israel

🇮🇱

Soroka Medical Center, Beer Sheba, Israel

🇮🇱

Hadassah Medical Center, Jerusalem, Israel

and more 8 locations

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

Terminated
Conditions
Cirrhosis
First Posted Date
2006-09-12
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
200
Registration Number
NCT00375011
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

🇺🇸

Department of Veteran Affairs, Richmond, Virginia, United States

🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

BreathID Multi-center HCV Liver Breath Test Study

Phase 2
Terminated
Conditions
Hepatitis C
Interventions
Other: MBT and BreathID
First Posted Date
2006-07-11
Last Posted Date
2022-12-20
Lead Sponsor
Meridian Bioscience, Inc.
Target Recruit Count
75
Registration Number
NCT00350714
Locations
🇺🇸

U.S. Dept. of Veteran Affairs, Hunter Holmes McGuire Medical Center, Richmond, Virginia, United States

🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

🇺🇸

Virginia Commonwealth Univeristy, Richmond, Virginia, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath